80 FR 44139 - National Institute on Aging; Amended Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 80, Issue 142 (July 24, 2015)

Page Range		44139-44139
FR Document		2015-18191

Federal Register, Volume 80 Issue 142 (Friday, July 24, 2015)

[Federal Register Volume 80, Number 142 (Friday, July 24, 2015)]
[Notices]
[Page 44139]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2015-18191]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Aging; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the National 
Institute on Aging Special Emphasis Panel, August 13, 2015, 12:00 p.m. 
to August 13, 2015, 4:00 p.m., National Institute on Aging, Gateway 
Building, 7201 Wisconsin Avenue, 2C212, Bethesda, MD 20892 which was 
published in the Federal Register on July 21, 2015, 80 FR 43101.
    The meeting notice is amended to change the date of the meeting 
from August 13, 2015 to August 12, 2015. The meeting is closed to the 
public.

    Dated: July 21, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-18191 Filed 7-23-15; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 80, No. 142 / Friday, July 24, 2015 / Notices 44139

DEPARTMENT OF HEALTH AND Aging Special Emphasis Panel, August thereby activating the T cell through the
HUMAN SERVICES 13, 2015, 12:00 p.m. to August 13, 2015, protein signalling domain. Once
4:00 p.m., National Institute on Aging, activated, the T cells selectively
National Institutes of Health Gateway Building, 7201 Wisconsin eliminate the cells which they
Avenue, 2C212, Bethesda, MD 20892 recognize. By engineering a T cell to
Eunice Kennedy Shriver National which was published in the Federal express CARs with antibody binding
Institute of Child Health and Human Register on July 21, 2015, 80 FR 43101. fragments which are specific for cell
Development; Notice of Closed The meeting notice is amended to surface proteins that are associated with
Meeting change the date of the meeting from diseased cells, it is possible to treat the
Pursuant to section 10(d) of the August 13, 2015 to August 12, 2015. The disease. This is a promising new
Federal Advisory Committee Act, as meeting is closed to the public. therapeutic approach known as
amended (5 U.S.C. App.), notice is Dated: July 21, 2015. adoptive cell therapy.
hereby given of the following meeting. Melanie J. Gray, CD22 and CD19 are cell surface
The meeting will be closed to the Program Analyst, Office of Federal Advisory
proteins that are expressed on a large
public in accordance with the Committee Policy. number of B cell lineage hematological
provisions set forth in section 552b(c)(4) [FR Doc. 2015–18191 Filed 7–23–15; 8:45 am]
cancers, such as leukemia and
and 552b(c)(6), Title 5 U.S.C., as lymphoma. CD19 CAR T cells have
BILLING CODE 4140–01–P
amended. The grant applications and demonstrated potent activity against
the discussions could disclose leukemia in early clinical trials.
confidential trade secrets or commercial DEPARTMENT OF HEALTH AND However, some of these patients will
property such as patentable material, HUMAN SERVICES relapse with leukemia that no longer
and personal information concerning expresses the CD19 protein. This
individuals associated with the grant National Institutes of Health technology concerns the use of two high
applications, the disclosure of which affinity antibody binding fragments as
would constitute a clearly unwarranted Government-Owned Inventions; the targeting moieties of a CAR: One to
invasion of personal privacy. Availability for Licensing CD22 (m971), and one against CD19
AGENCY: National Institutes of Health, (FMC63). The resulting CAR can be
Name of Committee: National Institute of
Child Health and Human Development HHS. used in adoptive cell therapy treatment
Special Emphasis Panel Improving Health for cancers which express either CD22
ACTION: Notice.
through Rehabilitation Robotic Technology. or CD19.
Date: August 19, 2015. SUMMARY: The inventions listed below Potential Commercial Applications:
Time: 1:00 p.m. to 3:00 p.m. are owned by an agency of the U.S. • Treatment of diseases associated
Agenda: To review and evaluate grant Government and are available for with increased or preferential
applications. licensing in the U.S. in accordance with expression of CD22 or CD19.
Place: National Institutes of Health, 6100
35 U.S.C. 209 and 37 CFR part 404 to • Specific diseases include
Executive Boulevard, Rockville, MD 20852 hematological cancers such as chronic
(Telephone Conference Call). achieve expeditious commercialization
of results of federally-funded research lymphocytic leukemia (CLL), hairy cell
Contact Person: Sathasiva B. Kandasamy,
Ph.D., Scientific Review Officer, Scientific and development. Foreign patent leukemia (HCL) acute lymphoblastic
Review Branch, Eunice Kennedy Shriver applications are filed on selected leukemia (ALL) and lymphoma.
National Institute of Child Health and inventions to extend market coverage Competitive Advantages:
Human Development, NIH, 6100 Executive for companies and may also be available • High affinity of the m971 and
Boulevard, Room 5B01, Bethesda, MD for licensing. FMC63 antibody binding fragments
20892–9304, (301) 435–6680, skandasa@
FOR FURTHER INFORMATION CONTACT:
increases the likelihood of successful
mail.nih.gov. targeting.
Licensing information and copies of the
(Catalogue of Federal Domestic Assistance
U.S. patent applications listed below • Targeted two antigens expressed on
Program Nos. 93.864, Population Research; the same type of diseased cells may
93.865, Research for Mothers and Children; may be obtained by writing to the
indicated licensing contact at the Office increase efficacy relative to targeting a
93.929, Center for Medical Rehabilitation single antigen.
Research; 93.209, Contraception and of Technology Transfer, National
• Targeted therapy decreases non-
Infertility Loan Repayment Program, National Institutes of Health, 6011 Executive
specific killing of healthy, essential
Institutes of Health, HHS) Boulevard, Suite 325, Rockville,
cells, resulting in fewer non-specific
Maryland 20852–3804; telephone: 301–
Dated: July 17, 2015. side-effects and healthier patients.
496–7057; fax: 301–402–0220. A signed
Michelle Trout, • Hematological cancers are
Confidential Disclosure Agreement will
Program Analyst, Office of Federal Advisory susceptible to cytotoxic T cells because
be required to receive copies of the
Committee Policy. they are present in the bloodstream.
patent applications.
[FR Doc. 2015–18093 Filed 7–23–15; 8:45 am] Development Stage:
SUPPLEMENTARY INFORMATION: • In vitro data available.
BILLING CODE 4140–01–P Technology descriptions follow. • In vivo data available (animal).
Bispecific Chimeric Antigen Receptors Inventors: Terry J. Fry, et al. (NCI).
DEPARTMENT OF HEALTH AND to CD22 and CD19 for Treating Publications:
asabaliauskas on DSK5VPTVN1PROD with NOTICES

HUMAN SERVICES Hematological Cancers 1. Haso W, et al. Anti-CD22-chimeric antigen
Description of Technology: Chimeric receptors targeting B-cell precursor acute
National Institutes of Health antigen receptors (CARs) are hybrid lymphoblastic leukemia. Blood. 2013
Feb 14;121(7):1165–74. [PMID 23243285]
National Institute on Aging; Amended proteins that have antibody binding 2. Lee DW, et al. T cells expressing CD19
Notice of Meeting fragments fused to protein signaling chimeric antigen receptors for acute
domains that activate T cells. The lymphoblastic leukaemia in children and
Notice is hereby given of a change in antibody binding fragments allow the young adults: a phase 1 dose-escalation
the meeting of the National Institute on CAR to recognize specific cell types, trial. Lancet. 2015 Feb7;385(9967):517–

VerDate Sep<11>2014 19:59 Jul 23, 2015 Jkt 235001 PO 00000 Frm 00121 Fmt 4703 Sfmt 4703 E:\FR\FM\24JYN1.SGM 24JYN1

Document Created: 2018-02-23 09:25:20
Document Modified: 2018-02-23 09:25:20

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
FR Citation		80 FR 44139

80 FR 44139 - National Institute on Aging; Amended Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 80, Issue 142 (July 24, 2015)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health